Researchers discover a wound-healing repair in gut diseases

An international team led by the Case Western Reserve University School of Medicine has discovered novel properties of the protein Gasdermin B that promotes repair of cells lining the gastrointestinal tract in people with chronic inflammatory disorders like Crohn’s disease and ulcerative colitis.

This article is a repost which originally appeared on ScienceDaily

Case Western Reserve University - February 7, 2022
Edited for content and readability - Images sourced from Pexels 
Source: DOI: 10.1016/j.cell.2021.12.024

Our Takeaways:

  • Gasdermins are a type of proteins that cause cell death
  • Gasdermin B is an exception – instead it keeps the gastrointestinal tract healthy
  • Future therapies investigating Gasdermin B could produce effective wound-healing of the lungs, skin and other organs

The new findings, recently published in the journal, Cell, are significant because the impact of Gasdermin B (GSDMB) on healing epithelium — a type of body tissue that lines the organs that have direct contact with the external environment — will play a key role in research on wound formation and designing novel therapeutics to enhance wound repair, said Theresa Pizarro, lead study author and the Louis Pillemer Professor of Experimental Pathology at the School of Medicine. In addition to medical school colleagues on campus, researchers included scientists from Cleveland Clinic, Texas, England and Greece.

Gasdermin B

Gasdermins are a family of proteins known to cause pyroptosis — a type of cell death usually triggered by infections and inflammation that contributes to conditions like ulcerative colitis and Crohn’s disease.

Within that protein family, Gasdermin B (GSDMB), unlike other gasdermin proteins, doesn’t cause pyroptosis, especially in epithelial cells, but instead contributes to keeping the gastrointestinal tract healthy — a significant discovery for the development of future therapeutic treatments.

Previous research has shown that individuals carrying genetic variations of Gasdermin B have an increased risk of developing inflammatory disorders like asthma or inflammatory bowel disease (IBD).

“Little was known regarding the mechanisms of how this occurred,” Pizarro said. “In our studies, we uncovered the functional consequences of these GSDMB genetic variants.”

“So, although IBD patients may produce higher levels of GSDMB when they have disease flares,” she said, “the GSDMB protein produced by the genetic variants interferes with the ability of epithelial cells to regenerate and form a healthy barrier critical to healing, for example, in ulcers of patients with ulcerative colitis.”

The study

The scientists analyzed samples from Crohn’s disease and ulcerative colitis patients using state-of-the-art techniques, such as single-cell RNA sequencing, CRISPR/Cas9 and epithelial organoid cultures. Results confirmed substantial increases of GSDMB in biopsies of those with IBD, particularly ulcerative colitis, when compared to levels of GSDMB found in healthy individuals.

The findings unexpectedly showed the lack of epithelial cell death due to GSDMB; instead, this increased level led to:

  • Proliferation, or the growth of new cells;
  • Migration, or the movement of cells;
  • And decreased adhesion dynamics — the attractive forces between cells and other surfaces that affect motility.

Together, these processes promote restoration of the epithelial layer and effective wound-healing, Pizarro said.

“Future therapies targeting gasdermin B are not necessarily restricted to IBD or other chronic inflammatory states of the gastrointestinal tract,” Pizarro said, “but also have far-reaching implications for effective wound-healing of the lungs, skin and other organs interfacing with the external environment that require maintenance of an efficient epithelial barrier.”

Pizarro credited “this groundbreaking discovery on the collaborative and concerted efforts from immunologists, gastroenterologists, cell biologists and bioinformaticians from around the world,” including from Oxford University, University of Athens, Baylor College of Medicine, UT Southwestern and her colleagues at Cleveland Clinic Lerner Research Institute and Case Western Reserve.

Gut Microbiome Metabolism and Lethal Prostate Cancer Risk

  • Gut bacteria convert some food molecules into metabolites that have strong associations with the development of aggressive prostate cancer.
  • Men with higher levels of these metabolites have a greater risk of lethal prostate cancer.
  • These molecules may be useful as early biomarkers of the disease.
  • By modifying diet and lifestyle, men may be able to reduce their risk of lethal prostate cancer.
This article is a repost which originally appeared on MedicalNewsToday
Katharine Lang - November 4, 2021
Fact checked by Anna Guildford, Ph.D.
Edited for content and readability - Images sourced from Pexels 
Study: https://cebp.aacrjournals.org

A study has shown that there may be an association between diet, the gut microbiome, and lethal prostate cancer.

The study, from the Cleveland Clinic, appears in Cancer Epidemiology, Biomarkers & Prevention.

Researchers used data from the PLCO cancer screening trial, a randomized control trial of 148,000 people. It involved screening 76,685 men aged between 55 and 74 for prostate cancer and then monitoring them for up to 13 years.

Researchers analyzed baseline levels of certain dietary nutrients and metabolites from nearly 700 men. Of these, 173 later died of prostate cancer. The median time between baseline sampling and death for those who developed lethal prostate cancer was 11.69 years.

“Men with higher levels of certain diet-related molecules are more likely to develop aggressive prostate cancer.”

– Dr. Nima Sharifi, MD, Director, Genitourinary Malignancies Research Center, Kendrick Family Endowed Chair for Prostate Cancer Research, Cleveland Clinic, lead researcher on the study

The researchers matched those who died for age, race, time of blood sample, and enrolment date with controls in a ratio of 1:3. Of the 519 men in the control sample, 83.6% remained healthy, and 16.4% had a subsequent non-lethal prostate cancer diagnosis during the study period.

On enrolling in the PLCO cancer screening trial, all participants gave blood samples. Researchers analyzed the blood serum for several different metabolites, some of which are formed by gut bacteria from food intake. They compared results from men who later died of prostate cancer with controls.

Increased risk

The researchers found associations between more aggressive prostate cancer and three metabolites – phenylacetylglutaminecholine, and betaine.

Phenylacetylglutamine is produced when gut bacteria break down phenylalanine, an essential amino acid. Choline and betaine are in some foods, as well as being formed by gut bacteria.

Phenylalanine is in high protein foods, such as dairy, meat, poultry, soy, fish, beans, nuts, and diet sodas sweetened with aspartame. It is an essential part of many proteins and enzymes in the body and, when converted to tyrosine, is used to make the neurotransmitter dopamine.

Choline is found mainly in animal products, such as meat, fish, eggs, and dairy, although pulses, nuts, and seeds are sources for vegans. Foods high in betaine include shellfish, wheat, spinach, and beets.

The researchers found that men with elevated phenylacetylglutamine in their blood serum at the start of the study were 2.5 times more likely to die of prostate cancer than those with the lowest levels. Men with increased choline or betaine had almost twice the risk of lethal prostate cancer as controls.

Dr. Sharifi commented: “[Our findings] suggest that food intake has a complex interaction with gut bacteria to affect lethal prostate cancer risk.”

Some gut bacteria convert choline and betaine into trimethylamine and trimethylamine N-oxide (TMAO), which a previous study found may also increase the risk of cardiovascular and neurological disorders. This is the first study to show an association between precursors of TMAO and cancer.

“Betaine and choline are being converted into more toxic chemicals in some. This does not mean they are bad for everyone. It’s the diet-microbe interaction that leads to the cancer.”

— Prof. Tim Spector, Professor of Genetic Epidemiology, King’s College, London, and Zoe Study Lead.

Diet could make a difference

Studies have shown that reducing meat intake has associations with lower mortality from cardiovascular disease and cancers. This study would appear to reinforce that message for prostate cancer.

As Dr. Sharifi says: “Generally, the metabolites associated with lethal prostate cancer are found to be enriched in meat and other animal products.”

However, Prof. Spector cautioned: “These metabolites are ubiquitous. It’s difficult to cut them out.”

The authors stress that although this study shows an association between the three metabolites and lethal prostate cancer, it cannot demonstrate a causal link. Dr. Sharifi and his team are undertaking further studies to determine “how metabolism in humans interacts with prostate cancer.”

Prof. Spector believes that the study: “Adds to the story building on how diet affects cancer mediated by the gut microbiome. We are reversing decades of doctors saying it doesn’t really matter what you eat.”